Top Page
Agronomics
(LSE:ANIC)
Agronomics (ANIC) vs. iShares MSCI United Kingdom ETF (EWC)
Agronomics Business Overview & Revenue Model
Agronomics Financial Statement Overview
| Breakdown | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | -11.92M | -8.34M | 29.70M | 440.32K | 10.67M |
| Gross Profit | 0.00 | -8.34M | 29.70M | 440.32K | 10.67M |
| EBITDA | -26.47M | 0.00 | 0.00 | 1.50M | 0.00 |
| Net Income | -32.75M | -10.99M | 22.37M | 8.36M | 1.02M |
Balance Sheet | |||||
| Total Assets | 124.67M | 157.44M | 170.20M | 146.40M | 101.65M |
| Cash, Cash Equivalents and Short-Term Investments | 124.62M | 12.24M | 169.87M | 146.30M | 101.21M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 147.60K | 166.17K | 1.95M | 2.49M | 1.62M |
| Stockholders Equity | 124.52M | 157.27M | 168.26M | 143.91M | 100.03M |
Cash Flow | |||||
| Free Cash Flow | -1.12M | -15.86M | -23.67M | -42.21M | -12.17M |
| Operating Cash Flow | -1.12M | -15.86M | -23.67M | -42.21M | -12.17M |
| Investing Cash Flow | 1.59M | 892.00K | 10.02M | -20.02M | -11.21M |
| Financing Cash Flow | 1.71K | 1.68K | 1.01M | 31.25M | 71.82M |
Agronomics Technical Analysis
Agronomics Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | $18.00B | 11.42 | 9.92% | 3.81% | 9.73% | 1.22% | |
67 Neutral | £125.63M | 37.82 | 1.79% | 3.29% | -9.37% | ― | |
63 Neutral | £772.23M | 7.53 | 8.92% | ― | 11.00% | ― | |
62 Neutral | £172.71M | 8.95 | 16.48% | 17.93% | -16.53% | -44.15% | |
52 Neutral | £16.22M | -6.05 | -14.80% | ― | 30.40% | 23.48% | |
50 Neutral | £494.72M | -3.99 | -14.23% | ― | ― | 33.10% | |
44 Neutral | £68.25M | -4.19 | -10.74% | ― | ― | -600.00% |
Agronomics Corporate Events
Agronomics reported a sharp turnaround to a net profit of £10 million for the six months to 31 December 2025, driven by £10.7 million of net investment gains and only modest operating costs. Net asset value per share rose 11.7% to 13.78 pence and total net assets increased to £140 million, although the shares continued to trade at a steep 55% discount to NAV, underlining persistent investor caution.
Portfolio value was buoyed by fair value gains in Blue Nalu and Liberation Bioindustries, foreign-exchange tailwinds and share-based deal structures, partially offset by a prior £11.9 million write-down of Meatable. Operationally, several holdings achieved important regulatory and commercial milestones, notably GRAS approvals for novel ingredients and capacity expansions, reinforcing Agronomics’ strategic positioning in alternative proteins despite a challenging funding environment for clean food start-ups.
Post period-end, Agronomics deepened its exposure to precision-fermented dairy by investing a further AU$3 million in All G through the issue of new shares at close to NAV. The company also continued to support later-stage portfolio names such as SuperMeat, EVERY Company and Blue Nalu via follow-on investments, indicating an active capital deployment strategy into companies it sees as best placed to scale.
The most recent analyst rating on (GB:ANIC) stock is a Hold with a £5.50 price target. To see the full list of analyst forecasts on Agronomics stock, see the GB:ANIC Stock Forecast page.
Agronomics Limited announced that all resolutions proposed at its Annual General Meeting held on 13 February 2026 were duly passed. The approval of all AGM resolutions provides the company with shareholder backing for its current strategy and governance framework, reinforcing its position in the clean food sector and offering continuity for investors and other stakeholders.
This outcome signals stability in Agronomics Limited’s corporate direction, supporting ongoing initiatives in sustainable food technologies. With no contested items reported, the AGM results suggest broad shareholder alignment with the board’s plans as the company continues to advance its clean food investment agenda.
The most recent analyst rating on (GB:ANIC) stock is a Hold with a £5.50 price target. To see the full list of analyst forecasts on Agronomics stock, see the GB:ANIC Stock Forecast page.
Agronomics has invested a further AU$3 million in Australian biotech All G, which uses precision fermentation to produce human and bovine milk proteins, notably animal‑free lactoferrin for applications in infant and clinical nutrition, functional foods, skincare and animal nutrition. The funding, made via a convertible note as part of a wider AU$10 million round and settled through the issue of 10,026,375 new Agronomics shares, will support All G’s commercial‑scale production, regulatory work and expansion in Asia and Europe after it secured pioneering approvals for recombinant bovine lactoferrin in China and self‑affirmed GRAS status in the US; post‑transaction, Agronomics’ total investment in All G rises to about £8.9 million and its own share capital increases to 1,056,575,208 shares, with potential implications for shareholder notifications under disclosure rules.
The most recent analyst rating on (GB:ANIC) stock is a Hold with a £6.00 price target. To see the full list of analyst forecasts on Agronomics stock, see the GB:ANIC Stock Forecast page.
Agronomics reported a sharp decline in performance for the year to 30 June 2025, with net asset value per share falling 20% to 12.34 pence and a swing to a £32.7 million net operating loss, driven largely by £25.1 million of net investment losses, adverse foreign exchange movements and significant write-downs, including the full impairment of its £11.9 million stake in Meatable following that company’s voluntary liquidation. Total assets fell to £124.7 million and cash balances dropped to £3.6 million, underscoring tighter financial conditions even as the group continued to support key holdings such as Liberation Bioindustries and SuperMeat through follow-on funding.
Despite the financial hit, the portfolio achieved notable regulatory and commercial milestones that strengthen Agronomics’ strategic position in cellular agriculture, with Meatly securing first-in-world approvals and sales for cultivated pet food in the UK and Europe, Solar Foods listing in Finland and expanding partnerships with Ajinomoto, and All G gaining Chinese regulatory clearance for recombinant bovine lactoferrin. Additional progress included new manufacturing and offtake partnerships for Liberation Bioindustries, expanded collaboration for BlueNalu in European cultivated seafood, and multiple regulatory clearances for alternative proteins and specialty oils, suggesting that while sector funding has tightened and weaker players are being written off, leading assets in Agronomics’ portfolio are edging closer to commercial scale and diversified revenue streams. The company also set 13 February 2026 for its AGM, encouraging shareholders to exercise their voting rights by proxy and engage with management ahead of the meeting.
The most recent analyst rating on (GB:ANIC) stock is a Buy with a £15.90 price target. To see the full list of analyst forecasts on Agronomics stock, see the GB:ANIC Stock Forecast page.
Agronomics has deepened its exposure to cultivated seafood pioneer BlueNalu with a US$6 million equity subscription in new preferred shares and a further US$600,000 investment in BlueNalu’s 2025 convertible promissory note round, taking its fully diluted stake to an expected 12.96%. The equity leg of the deal is being settled through the issuance of 30,643,003 new Agronomics ordinary shares at the company’s latest reported net asset value per share, while the CPNs, part of an approximately US$8 million round led by specialist food-tech investors, will convert into preferred stock on favourable terms upon a qualifying fundraise. The new Agronomics shares issued to BlueNalu are subject to a one-year lock-in and orderly market restrictions, and admission of the enlarged share capital to AIM is expected around 7 January 2026, implying modest dilution for existing shareholders but reinforcing Agronomics’ strategic bet on cell-cultivated seafood as BlueNalu advances regulatory engagement, commercial launch preparations for its cultivated bluefin tuna toro, and broader value-chain partnerships.
The most recent analyst rating on (GB:ANIC) stock is a Buy with a £15.90 price target. To see the full list of analyst forecasts on Agronomics stock, see the GB:ANIC Stock Forecast page.
Agronomics has announced that its portfolio company Meatable B.V. will be dissolved and all operating activities terminated after the cultivated meat business failed to secure continued funding from existing or new investors. The board and shareholders opted for an orderly wind-down under statutory liquidation procedures, leading Agronomics to write down its £11.9 million carrying value in Meatable to zero, crystallising the loss of its £7.9 million total investment, which represented about 8.1% of its net asset value as of 30 September 2025; despite the setback, the company stressed it remains focused on actively managing and supporting the rest of its portfolio with strong long-term growth prospects.
The most recent analyst rating on (GB:ANIC) stock is a Buy with a £15.90 price target. To see the full list of analyst forecasts on Agronomics stock, see the GB:ANIC Stock Forecast page.
Agronomics has strengthened its position in precision fermentation by announcing that portfolio company Liberation Bioindustries has closed the first tranche of its Series A1 equity round, supporting the completion of a 600,000-litre commercial-scale biomanufacturing facility in the US. The plant will produce bio-based proteins and other food ingredients for consumer goods and industrial manufacturers, underpinned by recent partnerships with Vivici to produce dairy protein Vivitein BLG at commercial volumes and with NEOM’s food company Topian to co-develop a fermentation facility in Saudi Arabia. As part of the round, Agronomics has converted all its convertible loan notes into Series A1 shares, increasing its holding from 6,834,147 to 16,538,437 shares, and now carries its total US$27 million investment in Liberation Bioindustries at US$46.8 million, equivalent to about 23% of its last reported net asset value; an affiliate, New Agrarian Company, will also invest US$2.5 million, underscoring Agronomics’ conviction that Liberation’s infrastructure will be a key asset in reshaping ingredient production and bolstering food and supply-chain security.
The most recent analyst rating on (GB:ANIC) stock is a Buy with a £15.90 price target. To see the full list of analyst forecasts on Agronomics stock, see the GB:ANIC Stock Forecast page.
Agronomics Limited has announced a US$ 2 million investment in SuperMeat, a company specializing in cultivated meat, as part of a US$ 3.5 million funding round. This investment will support SuperMeat’s efforts to commercialize its cultivated chicken production in Europe, which is noted for its reduced carbon emissions and cost-efficiency compared to conventional farming. The investment aligns with Agronomics’ strategy to promote sustainable food production, reflecting a strategic shift towards a cleaner and technologically advanced future for food.
The most recent analyst rating on (GB:ANIC) stock is a Buy with a £15.90 price target. To see the full list of analyst forecasts on Agronomics stock, see the GB:ANIC Stock Forecast page.